decitabin
cytosin
analog
pharmacokinet
incorpor
dna
methyl
histor
yield
clinic
respons
patient
acut
myeloid
leukemia
aml
myelodysplast
syndrom
md
across
divers
clinic
trial
although
respons
rate
may
higher
use
versu
approach
gener
decitabin
well
toler
given
outpati
set
decitabin
treatment
associ
infect
complic
readmiss
neutropen
fever
limit
data
exist
concern
type
infect
occur
aml
md
patient
treat
decitabin
recent
complet
studi
aml
md
patient
treat
decitabin
administ
daili
dose
per
cycl
similar
other
observ
modestli
higher
respons
rate
use
regimen
versu
publish
result
regimen
major
common
terminolog
criteria
advers
event
ctcae
signific
advers
event
sae
observ
associ
infecti
complic
readmiss
neutropen
fever
also
observ
respons
correl
presenc
mutat
antibiot
prophylaxi
controversi
aml
chemotherapi
decitabin
treatment
benefit
prophylaxi
unclear
studi
review
sae
observ
among
patient
determin
whether
infecti
complic
observ
decitabin
treatment
might
differ
complic
intens
regimen
whether
specif
bacteria
commonli
observ
might
amen
altern
prophylaxi
review
ctcae
version
grade
sae
associ
infecti
complic
patient
aml
md
enrol
april
novemb
clinic
studi
washington
univers
school
medicin
patient
event
document
cultur
result
could
retrospect
evalu
studi
approv
institut
review
board
conduct
accord
provis
declar
helsinki
respons
evalu
molecular
previous
publish
decitabin
administ
intraven
dose
bodi
surfac
area
per
day
cycl
initi
cycl
given
consecut
day
patient
achiev
blast
could
reduc
dose
day
two
cycl
dose
day
dose
could
reduc
day
prophylact
antimicrobi
therapi
recommend
stipul
part
studi
recommend
prophylaxi
consist
acyclovir
ciprofloxacin
fluconazol
patient
develop
complic
treat
antimicrobi
support
therapi
accord
commonli
accept
guidelin
diagnost
case
fever
includ
collect
blood
cultur
central
venou
cathet
peripher
vein
collect
nasal
pharyng
anal
swab
standard
chest
radiograph
obtain
hospit
admiss
clinic
indic
cytomegaloviru
cmv
reactiv
routin
test
prompt
empir
therapi
consist
cephalosporin
penicillin
carbapenem
antibiot
vancomycin
ad
fever
persist
h
least
one
follow
clinic
find
met
clinic
suspect
seriou
infect
known
colon
pneumococci
staphylococcu
aureu
posit
blood
cultur
bacteria
final
identif
hypotens
evid
cardiovascular
impair
azol
echinocandin
given
empir
patient
respond
antibiot
therapi
within
day
modif
antibiot
therapi
made
basi
result
cultur
suscept
microorgan
antimicrobi
agent
record
seriou
advers
event
review
fever
consid
singl
temperatur
measur
least
h
absenc
obviou
environment
caus
neutropenia
defin
absolut
neutrophil
count
anc
less
anc
categor
accord
whether
onset
febril
episod
caus
agent
identifi
classifi
bacteri
mycobacteri
fungal
candida
speci
aspergillu
speci
viral
varicella
zoster
viru
herp
simplex
viru
hsv
site
infect
classifi
blood
bacteremia
skin
andor
soft
tissu
blood
stream
infect
gastrointestin
gi
tract
upper
respiratori
tract
pharyng
sinus
rhiniti
lower
respiratori
tract
pneumonia
bronchiti
urinari
tract
jointbon
septic
arthriti
osteomyel
outcom
infect
patient
determin
complet
antimicrobi
therapi
patient
die
infect
consid
failur
data
analyz
novemb
statist
analysi
perform
use
spss
program
version
ibm
chicago
il
univari
analysi
fisher
exact
test
pearson
use
assess
infect
incid
p
consid
statist
signific
distribut
overal
surviv
describ
use
curv
compar
test
surviv
analysi
perform
use
prism
graphpad
san
diego
ca
total
number
cycl
decitabin
administ
patient
aml
md
tabl
fifti
patient
male
femal
median
age
patient
popul
year
rang
year
median
number
cycl
receiv
rang
two
hundr
hospit
admiss
follow
administr
decitabin
review
admiss
febril
episod
infect
total
admiss
mortal
mortal
surviv
clinic
featur
patient
without
event
shown
tabl
clinic
featur
correl
incid
sae
gender
age
perform
statu
diseas
respons
cycl
complet
median
mode
number
sae
per
patient
subgroup
tabl
incid
sae
correl
cycl
number
fig
averag
within
cycl
approxim
one
third
patient
receiv
cycl
experienc
sae
observ
consist
reduct
incid
higher
number
cycl
ie
cycl
overal
median
surviv
cohort
day
counterintuit
patient
without
sae
shorter
surviv
median
day
vs
day
patient
sae
respect
perhap
remain
therapi
long
enough
experi
complic
fig
univari
analysi
compar
patient
infect
versu
one
patient
younger
age
age
tend
higher
incid
infect
howev
older
patient
shorter
surviv
may
account
disproportion
number
older
patient
without
event
fig
nevertheless
differ
infect
incid
two
group
vs
reach
statist
signific
p
likewis
compar
infect
incid
aml
patient
higher
incid
infect
note
md
patient
p
howev
aml
patient
also
shorter
surviv
compar
md
patient
fig
therefor
patient
live
longer
therapi
tend
infect
episod
although
develop
multipl
infect
affect
overal
surviv
compar
patient
experienc
one
two
infect
fig
blood
count
result
prospect
record
day
cycl
day
cycl
day
end
even
cycl
neutropenia
common
across
fig
total
patient
anc
two
measur
respect
time
sae
anc
retrospect
assess
major
patient
neutropenia
anc
anc
onset
infect
half
patient
present
anc
fig
event
record
admiss
antibacteri
antivir
antifung
prophylact
agent
review
tabl
major
admiss
patient
document
receiv
antivir
prophylaxi
fewer
patient
document
receiv
antibacteri
antifung
prophylaxi
admiss
patient
alreadi
receiv
antibacteri
prophylaxi
posit
cultur
bacteria
contrast
posit
cultur
note
admiss
patient
antibacteri
prophylaxi
p
valu
furthermor
two
six
posit
cultur
fungi
occur
set
antifung
prophylaxi
five
eight
viral
infect
occur
patient
receiv
antivir
prophylaxi
parainfluenza
hsv
rhinovirusenteroviru
admiss
clinic
suspect
infect
associ
neg
cultur
result
caus
agent
infect
document
admiss
infect
total
admiss
admiss
associ
mix
infect
two
differ
pathogen
viral
two
fungal
mycobacteri
total
number
pathogen
retriev
infecti
diagnost
workup
cultur
swab
etc
perform
admiss
tabl
bacteria
repres
total
isol
pathogen
staphylococci
includ
staphylococcu
epidermidi
repres
common
organ
follow
enterococcu
vre
pseudomona
speci
follow
escherichia
coli
frequent
pathogen
studi
popul
infect
caus
fungal
viral
agent
respect
lower
respiratori
tract
infect
common
site
infect
event
admiss
follow
bacteremia
event
admiss
tabl
understand
whether
indwel
cathet
might
influenc
frequenc
type
infect
review
admiss
chest
procedur
note
associ
hospit
hospit
patient
central
venou
cathet
hohn
twenti
implant
port
peripher
insert
central
cathet
picc
peripher
access
patient
hohn
picc
cathet
tend
infect
compar
patient
type
access
port
peripher
access
howev
correl
reach
statist
signific
p
organ
identifi
vancomycin
linezolid
frequent
associ
suscept
contrast
organ
frequent
suscept
cefepim
meropenem
gentamycin
cefepim
vancomycin
commonli
use
empir
antibiot
overal
admiss
ten
enterococcu
case
vre
two
staphylococcu
case
methicillin
resist
mrsa
one
e
coli
infect
caus
esbl
organ
prophylact
antibacteri
ciprofloxacin
bid
administr
five
case
case
resist
microorgan
mrsa
vre
esbl
prior
admiss
pseudomona
infect
sensit
carbapenem
complet
recoveri
infecti
complic
observ
major
patient
patient
discharg
prophylact
antibiot
ciprofloxacin
mg
bid
admiss
length
prophylaxi
indefinit
almost
half
case
studi
period
infect
requir
readmiss
within
week
total
seven
death
attribut
complic
overal
incid
patient
three
death
due
bacteremiasepsi
caus
pseudomona
e
coli
two
due
pneumonia
acut
respiratori
failur
one
due
mix
bacteremia
mycobacterium
abscessu
vre
one
due
pneumonia
associ
dissemin
fusarium
one
seven
case
prophylact
antibiot
prior
admiss
patient
receiv
quinolon
prophylaxi
time
sae
tend
fewer
posit
cultur
compar
receiv
prophylaxi
vs
although
reach
statist
signific
p
presenc
antibiot
prophylaxi
time
admiss
associ
statist
signific
higher
rate
resist
microorgan
p
lower
rate
mortal
p
two
case
clostridium
difficil
coliti
occur
set
prophylact
ciprofloxacin
treatment
one
rel
precis
data
avail
incid
characterist
bacteri
fungal
viral
caus
infect
aml
md
patient
treat
decitabin
studi
investig
retrospect
infecti
complic
occur
patient
aml
md
enrol
studi
describ
preval
characterist
clinic
microbiolog
defin
infect
mortal
relationship
number
cycl
event
well
effect
prophylaxi
posit
cultur
suscept
microorgan
neutropenia
common
across
cycl
therapi
fig
base
frequenc
durat
neutropenia
observ
cohort
current
guidelin
would
recommend
consist
quinolon
prophylaxi
consider
antifung
prophylaxi
grade
sae
occur
patient
therapi
observ
approxim
one
third
patient
cycl
compar
incid
infect
use
decitabin
regimen
longer
cours
therapi
associ
infect
studi
report
blum
et
al
howev
mortal
surviv
remain
compar
vs
vs
cohort
cohort
treat
regimen
respect
fever
infect
frequent
caus
hospit
patient
popul
major
event
associ
caus
agent
identifi
organ
isol
admiss
bacteria
repres
commonli
identifi
sourc
infect
microbiolog
clinic
document
fungal
viral
infect
diagnos
less
hospit
studi
ratio
bacteria
approach
cocci
predominantli
staphylococci
repres
frequent
isol
microorgan
find
surpris
consist
literatur
chemotherapeut
agent
hematolog
malign
well
solid
cancer
domin
pattern
attribut
widespread
use
indwel
intravascular
cathet
use
prophylaxi
target
organ
eg
ciprofloxacin
surgic
implant
tunnel
cathet
associ
lower
rate
bloodstream
infect
percutan
insert
cathet
studi
observ
nonsignific
trend
toward
greater
number
infect
patient
hohn
picc
cathet
might
expect
aml
md
patient
receiv
decitabin
frequent
present
cytopenia
unabl
obtain
surgic
implant
cathet
achiev
remiss
limit
opportun
altern
access
physician
cogniz
risk
opportun
pose
differ
form
percutan
access
enterococc
speci
especi
bacteria
repres
second
common
isol
popul
caus
mainli
bacteremia
urinari
tract
infect
nevertheless
rate
vre
infect
appear
similar
patient
compar
patient
undergo
induct
intens
chemotherapi
compar
although
colon
far
frequent
true
infect
even
immunocompromis
patient
bacteremia
vre
involv
outbreak
among
oncolog
patient
treat
chemotherapi
associ
increas
mortal
rate
viridan
group
streptococci
import
pathogen
classic
seen
patient
undergo
induct
intens
chemotherapi
associ
neutropenia
oropharyng
mucos
four
case
type
bacteremia
isol
patient
group
one
case
mucos
rare
decitabin
time
bacteremia
therefor
port
entri
gi
mucosa
central
venou
line
may
repres
potenti
sourc
infect
patient
mortal
cohort
associ
bacteremia
pneumonia
one
case
dissemin
fusarium
data
consist
histor
outcom
aerob
bacilli
e
coli
pseudomona
aeruginosa
focu
antibacteri
prophylaxi
target
bacteria
primari
prophylaxi
fluoroquinolon
patient
popul
associ
trend
toward
fewer
posit
blood
cultur
p
associ
higher
rate
resist
microorgan
lower
rate
mortal
fungal
infect
infrequ
recurr
caus
morbid
mortal
observ
incid
probableproven
invas
fungal
infect
includ
mix
infect
although
spectrum
fungal
pathogen
similar
commonli
aspergillu
speci
candida
speci
incid
may
modestli
lower
report
incid
rate
ifi
aml
patient
treat
intens
cytotox
therapi
nevertheless
consid
high
number
observ
clinic
suspect
infect
neg
cultur
exclud
incid
invas
fungal
infect
might
higher
similar
pattern
infecti
complic
report
aml
patient
intens
chemotherapi
review
adult
aml
treat
convent
chemotherapi
identifi
sourc
organ
febril
episod
although
bacteri
infect
also
frequent
caus
infecti
complic
infect
observ
ratio
modestli
higher
incid
fungal
infect
observ
sum
found
sae
common
aml
md
patient
undergo
decitabin
regimen
cohort
admiss
hospit
evalu
neutropen
fever
occur
major
patient
point
treatment
occur
nearli
one
third
patient
cycl
treatment
caus
agent
identifi
less
half
admiss
bacteria
frequent
agent
identifi
howev
infect
associ
mortal
although
expand
antimicrobi
prophylaxi
includ
better
coverag
eg
ampicillin
augmentin
could
reduc
incid
hospit
admiss
unlik
impact
overal
surviv
furthermor
downsid
approach
includ
toxic
potenti
promot
resist
consid
prospect
studi
need
determin
whether
benefit
antibacteri
prophylaxi
outweigh
risk
author
declar
conflict
interest
